HK1207366A1 - Thiadiazolidinediones as gsk-3 inhibitors gsk-3 - Google Patents
Thiadiazolidinediones as gsk-3 inhibitors gsk-3Info
- Publication number
- HK1207366A1 HK1207366A1 HK15107867.8A HK15107867A HK1207366A1 HK 1207366 A1 HK1207366 A1 HK 1207366A1 HK 15107867 A HK15107867 A HK 15107867A HK 1207366 A1 HK1207366 A1 HK 1207366A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- gsk
- thiadiazolidinediones
- inhibitors
- inhibitors gsk
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12382066 | 2012-02-24 | ||
PCT/EP2013/053554 WO2013124413A1 (en) | 2012-02-24 | 2013-02-22 | Thiadiazolidinediones as gsk-3 inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1207366A1 true HK1207366A1 (en) | 2016-01-29 |
Family
ID=47747639
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15107867.8A HK1207366A1 (en) | 2012-02-24 | 2015-08-14 | Thiadiazolidinediones as gsk-3 inhibitors gsk-3 |
Country Status (19)
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6073377B2 (ja) | 2012-02-24 | 2017-02-01 | エーエスディー セラピューティクス パートナーズ エルエルシーAsd Therapeutics Partners Llc | Gsk−3阻害剤としての新規チアジアゾリジンジオン |
ES2908026T3 (es) | 2013-03-14 | 2022-04-27 | Brigham & Womens Hospital Inc | Composiciones y procedimientos para la expansión y el cultivo de células madre epiteliales |
EP4306173A3 (en) * | 2014-06-12 | 2024-04-10 | Cedars-Sinai Medical Center | Compositions and methods for treating cancers |
CN107073042A (zh) | 2014-09-03 | 2017-08-18 | 布里格海姆妇女医院公司 | 用于产生内耳毛细胞来治疗听力损失的组合物、系统和方法 |
CA3010610A1 (en) | 2016-01-08 | 2017-07-13 | The Brigham And Women's Hospital, Inc. | Production of differentiated enteroendocrine cells and insulin producing cells |
US10213511B2 (en) | 2016-03-02 | 2019-02-26 | Frequency Therapeutics, Inc. | Thermoreversible compositions for administration of therapeutic agents |
US10201540B2 (en) | 2016-03-02 | 2019-02-12 | Frequency Therapeutics, Inc. | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I |
US11260130B2 (en) | 2016-03-02 | 2022-03-01 | Frequency Therapeutics, Inc. | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV |
JP7109446B2 (ja) | 2016-12-30 | 2022-07-29 | フリークエンシー セラピューティクス インコーポレイテッド | 幹細胞/前駆支持細胞の自己複製を誘導するための1h-ピロール-2,5-ジオン化合物およびその使用方法 |
EP3837352A1 (en) | 2018-08-17 | 2021-06-23 | Frequency Therapeutics, Inc. | Compositions and methods for generating hair cells by upregulating jag-1 |
WO2020037326A1 (en) | 2018-08-17 | 2020-02-20 | Frequency Therapeutics, Inc. | Compositions and methods for generating hair cells by downregulating foxo |
CN113168150B (zh) * | 2018-10-16 | 2024-05-10 | 意大利技术联盟有限责任公司 | 具有被处理幅材的评估系统的卷绕机和方法 |
AU2020218366A1 (en) | 2019-02-08 | 2021-09-16 | Frequency Therapeutics, Inc. | Valproic acid compounds and Wnt agonists for treating ear disorders |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CZ296087B6 (cs) | 2000-05-11 | 2006-01-11 | Consejo Superior Investigaciones Cientificas | Farmaceutický prostredek pro lécbu nemoci, na nízse podílí heterocyklické inhibitory glykogensyntázakinázy GSK-3 |
ES2166328B1 (es) * | 2000-05-11 | 2003-09-16 | Consejo Superior Investigacion | Inhibidores heterociclicos del enzima gsk 3 utiles en el tratamiento de procesos neurodegenerativos e hiperproliferativos |
EP1586318A1 (en) * | 2004-04-05 | 2005-10-19 | Neuropharma S.A.U. | Thiadiazolidinones as GSK-3 inhibitors |
KR100837785B1 (ko) * | 2007-01-17 | 2008-06-13 | 한국화학연구원 | 1,2,4-티아다이아졸리딘-3,5-다이온 화합물을 포함하는염증관련 질환의 치료 및 예방을 위한 약제학적 조성물 |
JP6073377B2 (ja) | 2012-02-24 | 2017-02-01 | エーエスディー セラピューティクス パートナーズ エルエルシーAsd Therapeutics Partners Llc | Gsk−3阻害剤としての新規チアジアゾリジンジオン |
-
2013
- 2013-02-22 JP JP2014558118A patent/JP6073377B2/ja active Active
- 2013-02-22 CA CA2865351A patent/CA2865351C/en active Active
- 2013-02-22 US US14/380,623 patent/US9371299B2/en active Active
- 2013-02-22 IN IN7885DEN2014 patent/IN2014DN07885A/en unknown
- 2013-02-22 DK DK13705492.0T patent/DK2838888T3/en active
- 2013-02-22 ES ES13705492.0T patent/ES2632428T3/es active Active
- 2013-02-22 HU HUE13705492A patent/HUE035089T2/hu unknown
- 2013-02-22 LT LTEP13705492.0T patent/LT2838888T/lt unknown
- 2013-02-22 WO PCT/EP2013/053554 patent/WO2013124413A1/en active Application Filing
- 2013-02-22 EP EP13705492.0A patent/EP2838888B1/en active Active
- 2013-02-22 NZ NZ630615A patent/NZ630615A/en unknown
- 2013-02-22 PL PL13705492T patent/PL2838888T3/pl unknown
- 2013-02-22 PT PT137054920T patent/PT2838888T/pt unknown
- 2013-02-22 AU AU2013224041A patent/AU2013224041B2/en active Active
- 2013-02-22 SI SI201330704T patent/SI2838888T1/sl unknown
-
2014
- 2014-08-25 ZA ZA2014/06225A patent/ZA201406225B/en unknown
-
2015
- 2015-08-14 HK HK15107867.8A patent/HK1207366A1/xx unknown
-
2016
- 2016-05-16 US US15/155,437 patent/US9469618B2/en active Active
-
2017
- 2017-01-04 JP JP2017000211A patent/JP6518270B2/ja active Active
- 2017-06-26 HR HRP20170964TT patent/HRP20170964T1/hr unknown
- 2017-07-12 CY CY20171100737T patent/CY1119231T1/el unknown
- 2017-10-20 AU AU2017248556A patent/AU2017248556B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP2838888A1 (en) | 2015-02-25 |
HUE035089T2 (hu) | 2018-05-02 |
WO2013124413A1 (en) | 2013-08-29 |
IN2014DN07885A (US07794700-20100914-C00152.png) | 2015-04-24 |
CA2865351A1 (en) | 2013-08-29 |
ZA201406225B (en) | 2016-05-25 |
DK2838888T3 (en) | 2017-07-17 |
JP2017081974A (ja) | 2017-05-18 |
PT2838888T (pt) | 2017-07-18 |
SI2838888T1 (sl) | 2017-09-29 |
AU2013224041B2 (en) | 2017-08-24 |
AU2013224041A1 (en) | 2014-09-25 |
PL2838888T3 (pl) | 2017-12-29 |
AU2017248556A1 (en) | 2017-11-09 |
JP6073377B2 (ja) | 2017-02-01 |
CA2865351C (en) | 2019-08-20 |
US9469618B2 (en) | 2016-10-18 |
CY1119231T1 (el) | 2018-02-14 |
EP2838888B1 (en) | 2017-04-12 |
US20150038538A1 (en) | 2015-02-05 |
ES2632428T3 (es) | 2017-09-13 |
US9371299B2 (en) | 2016-06-21 |
AU2017248556B2 (en) | 2018-08-09 |
HRP20170964T1 (hr) | 2017-10-06 |
JP6518270B2 (ja) | 2019-05-22 |
US20160257660A1 (en) | 2016-09-08 |
NZ630615A (en) | 2015-09-25 |
LT2838888T (lt) | 2017-08-10 |
JP2015508092A (ja) | 2015-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1210775A1 (en) | Imidazotriazinecarbonitriles useful as kinase inhibitors | |
HK1212348A1 (en) | Autotaxin inhibitors | |
HK1211921A1 (en) | Inhibitor compounds | |
HK1208442A1 (en) | Substituted pyrrolopyrimidinylamino-benzothiazolones as mknk kinase inhibitors mknk | |
HK1201200A1 (en) | Substituted pyrrolidine-2-carboxamides -2- | |
EP2920149A4 (en) | 3-AMINOCYCLOALKYL COMPOUNDS AS ROR-GAMMA-T-HEMMER AND USES THEREOF | |
HK1200830A1 (en) | Substituted pyrrolidine-2-carboxamides -2- | |
HK1207366A1 (en) | Thiadiazolidinediones as gsk-3 inhibitors gsk-3 | |
SG11201501173SA (en) | PI3Kδ INHIBITOR | |
SG11201500973WA (en) | Amino-quinolines as kinase inhibitors | |
HK1209422A1 (en) | Fbxo3 inhibitors fbxo3 | |
HK1209105A1 (en) | Vegfr3 inhibitors vegfr3 | |
HK1209104A1 (en) | Vegfr3 inhibitors vegfr3 | |
EP2934541A4 (en) | NORIBOGAINE SUBSTITUTE | |
GB201211019D0 (en) | Inhibitor compounds | |
ZA201504305B (en) | Autotaxin inhibitors | |
AP2015008541A0 (en) | Autotaxin inhibitors | |
GB201216008D0 (en) | Novel use of GSK-3 inhibitors |